Brii Biosciences Initiates Phase I Study for BRII-297 in Australia
China’s Brii Biosciences (HKG: 2137) has announced the first patient dosing in a Phase I...
AIM Vaccine’s Omicron BA.5 mRNA Vaccine Shows 73.16% Efficacy in China Trial
China-based AIM Vaccine Co., Ltd (HKG: 6660) has revealed the protective efficacy of its Omicron...
National Health Commission Unveils Action Plan for Medical Quality Improvement (2023-2025)
The National Health Commission (NHC) has released the “Action Plan for Comprehensive Improvement of Medical...
Coherus and Junshi Biosciences Await FDA Decision on Toripalimab After Inspection
US-based Coherus Biosciences Inc., (NASDAQ: CHRS) has disclosed that the US FDA has recently completed...
Betta Pharmaceuticals’ Befotertinib Approved by China’s NMPA for EGFR-Mutated NSCLC
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced receiving market approval from the National...
Antengene’s Xpovio Combination Therapy Approved for Reimbursement in Australia for R/R MM
China-based biotech Antengene Corp., Ltd (HKG: 6996) has revealed that Australia’s Pharmaceutical Benefits Scheme (PBS)...
Amoytop Biotech and Fosun Pharmaceutical Ink Licensing Deal for Pegfilgrastim in China
Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has announced a licensing agreement with Shanghai Fosun...
HighField Biopharmaceuticals Presents Promising HF1K16 Data at ASCO Annual Meeting
Hangzhou-based biotech HighField Biopharmaceuticals has revealed the publication of an abstract at this year’s American...
Luzhu Biotechnology’s Herpes Zoster Vaccine LZ901 Concludes Phase II Study
Beijing Luzhu Biotechnology Co., Ltd (HKG: 2480), a leading maker of human vaccines and therapeutic...
CMS Receives NMPA Approval for Tildrakizumab for Plaque Psoriasis Treatment
China Medical System Holdings (CMS; HKG: 0867) has announced receiving marketing approval from the National...
Cutia Therapeutics Lists on HKEX with HKD527 Million IPO for Dermatology Therapies
Dermatology therapy developer Cutia Therapeutics (HKG: 2487) has successfully made its initial public offering (IPO),...
CSPC Pharmaceutical’s AlaMab Therapeutics Presents Positive ALMB-0168 Data at ASCO
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its subsidiary, AlaMab Therapeutics Inc.,...
Betta Pharmaceuticals Secures Exclusive Rights to C4 Therapeutics’ CFT8919 in Greater China
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced an exclusive licensing agreement with US...
Lynk Pharmaceuticals Secures RMB 200 Million in Series C1 Financing Round
China-based Lynk Pharmaceuticals Co., Ltd has successfully raised RMB 200 million (USD 28.3 million) through...
Digital China Development Report Highlights Growth of Digital Healthcare Ecosystem
The Cyberspace Administration of China (CAC) has released the Digital China Development Report (2022), providing...
BeiGene’s Brukinsa Receives Canadian Approval for Chronic Lymphocytic Leukemia
China-based BeiGene Ltd (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced that its Bruton’s tyrosine...
Sanofi’s Commitment to China: Expansion, Digital Innovation, and Local R&D
Wayne Shi, president of France-based Sanofi’s (NASDAQ: SNY) Greater China business, has been discussing the...
XtalPi Partners with Eli Lilly for AI-Driven Drug Discovery Services
Sino-US artificial intelligence (AI) firm XtalPi Inc. has been enlisted by US-giant Eli Lilly &...
Chia Tai Tianqing’s Biosimilar Rituximab Approved by China’s NMPA for Lymphoma Treatments
China-based Chia Tai Tianqing has announced receiving a market approval from the National Medical Products...
Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for SHR-2106 and HRS-1893 Clinical Trials
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has separately announced receiving clinical trial approvals...